Drug Trial Radar · NCT06169722
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 6, 2024
Primary completion
Feb 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- Beijing Tide Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2. Phase II study stage: Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety
Conditions
- GVHD, Chronic
Interventions
TDI01 suspensionDrug
200mg or 400mg oral once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib study stage:The best overall response rate (BORR)Time frame: 24 weeks.
- Phase Ib study stage:adverse eventsTime frame: 24 weeks.
- Phase II study stage:The best overall response rate (BORR)Time frame: 24 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.